

## **MaSTherCell to become the global brand for Orgenesis' CDMO service offerings**

### **The MaSTherCell Global entity will deliver expanded harmonized development and manufacturing services**

GERMANTOWN, Md., – 22<sup>nd</sup> of January 2018 – Orgenesis Inc. (Orgenesis), a service and research company in the field of regenerative medicine industry with a focus on cell therapy development and manufacturing for advanced medicinal products and the parent company of MaSTherCell, has announced the branding of its global CDMO network under the name of MaSTherCell.

Orgenesis plans to transfer its interests in MaSTherCell S.A., Belgium, as well as its interests in its current joint venture partners in Israel and Korea, to a newly formed wholly-owned Delaware-based holding company, named MaSTherCell Global Inc. (MaSTherCell Global). This reorganization aims to create a more efficient corporate structure that can broaden, streamline and harmonize the CDMO service offerings on a global basis.

All CDMO network partners brought under MaSTherCell Global will use the MaSTherCell brand. In addition, At-Vio Biotech Inc., Orgenesis' Israel based CDMO partner, will be the technology innovation center of the network and focus its unique technology and innovation activity on offering process engineering to the global cell & gene therapy markets.

Following the corporate regrouping, the MaSTherCell Global service centers will continue to be located in Belgium, South Korea and Israel. The harmonization of the Quality System within each center enables an optimized and fast-track intercontinental technology transfer for worldwide clinical and commercial manufacturing services. All of the facilities will harmonize their CDMO service offerings with quality and standards provided by MaSTherCell Belgium – the center of excellence - as a natural step towards the harmonization of the global network.

Denis Bedoret, General Manager of MaSTherCell S.A., stated, “We are proud of the outcome of the collaborative effort of our global teams to ensure that the MaSTherCell brand and quality becomes internationally available. This is an impactful step to provide our customers with a global and streamlined service offering, and to uniquely position MaSTherCell as the only worldwide CDMO providing a harmonized quality system across all facilities.”

Romain de Rauville, Business Manager of MaSTherCell S.A., added, “We are enthusiastic to offer our current and future customers the extra ability to grow globally by providing seamless interfacility tech transfer, regulatory support for each market and have facilities strategically located to manufacture cell based material in optimal conditions. It is a perfect fit for the long term partnerships we nourish with our customers, enabling them to expand the reach of their breakthrough therapies in the most efficient way possible.”

### **About MaSTherCell S.A.**

MaSTherCell is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. The company is the subsidiary of Orgenesis Inc. (OTCQB:ORGS), a cell therapy and regenerative medicine company that is committed to developing a cure for Type 1 diabetes. The heart of MaSTherCell is a team of more than 100 highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and a substantial knowledge of the industry. From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell's teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. MaSTherCell S.A. operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin.  
More information: [www.masthercell.com](http://www.masthercell.com)

### **Contacts**

MaSTherCell S.A.

Tel: +32 71 34 81 19

Email: [info@masthercell.com](mailto:info@masthercell.com)

ATVIO Biotech Inc.

Email: [info@at-vio.com](mailto:info@at-vio.com)

### **Notice Regarding Forward-Looking Statements**

*This press release contains forward-looking statements that involve substantial uncertainties and risks relating to Orgenesis Inc.. These forward-looking statements are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, the risk that Orgenesis' planned corporate CDMO regrouping will not in fact be implemented or if implemented will not achieve its intended results, the difficulties in establishing the MaSTherCell brand in the global arena, the sufficiency of working capital to realize Orgenesis business plans, the development of our regeneration technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; our technology not functioning as expected; our ability to retain key employees; our ability to satisfy the rigorous regulatory requirements for new procedures; our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended November 30, 2016, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.*